【Anest Iwata】 Fiscal Year 2026 Full-Year Financial Results | Revenue of 5.59 billion yen (YoY +2.8%)

Performance Overview

Anest Iwata's consolidated performance for the fiscal year ending March 2026 recorded net sales of 5.59 billion yen (YoY +2.8%), operating profit of 556 million yen (5.8% decrease), ordinary income of 772 million yen (8.1% increase), and net profit of 536 million yen (25.2% increase). Steady overseas operations and improved profit margins led to a significant rise in net profit, with dividends increased to 87 yen. Cash flows included operating inflow of 814 million yen, investing outflow of 433 million yen, and financing outflow of 386 million yen, with cash on hand of 1.81 billion yen. Moving forward, the company plans to continue expanding overseas and pursuing M&A to achieve long-term growth.

Outlook and Impact on Shareholders

For the fiscal year ending March 2027, sales are projected at 6.0 billion yen (YoY +7.3%) and net profit at 395 million yen (26.3% decrease). The company will continue expanding into overseas markets and making new investments, aiming to enhance long-term corporate value. Dividends are expected to be 93 yen, emphasizing shareholder returns. Despite geopolitical risks and exchange rate fluctuations, the group will optimally allocate management resources and pursue sustainable growth.